Quick Answer
iBio, Inc. reported Operating Income of -$18.60 million for fiscal year 2025.
iBio, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$18.60M | -11.8% |
| 2024 | -$16.63M | +43.3% |
| 2023 | -$29.34M | +1.2% |
| 2022 | -$29.70M | +4.5% |
| 2021 | -$31.11M | -122.2% |
| 2020 | -$14.00M | +11.3% |
| 2019 | -$15.79M | -11.0% |
| 2018 | -$14.23M | +0.3% |
| 2017 | -$14.27M | -44.3% |
| 2016 | -$9.89M | -48.4% |
| 2015 | -$6.67M | -73.6% |
| 2014 | -$3.84M | +42.4% |
| 2013 | -$6.67M | +28.5% |
| 2012 | -$9.33M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$9.45M | -113.7% | -58.7% |
| September 30, 2025 | -$5.95M | -44.9% | -22.0% |
| March 31, 2025 | -$4.88M | -34.6% | -10.4% |
| December 31, 2024 | -$4.42M | +1.7% | -7.6% |
| September 30, 2024 | -$4.11M | +19.5% | -13.2% |
| March 31, 2024 | -$3.63M | +41.2% | +19.4% |
| December 31, 2023 | -$4.50M | +57.5% | +11.9% |
| September 30, 2023 | -$5.10M | +33.2% | +17.3% |
- iBio, Inc. showed a decrease of -11.8% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, iBio, Inc.’s operating income has declined by 99.4% (from -$9.33 million to -$18.60 million).
- The most recent figure is from iBio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 5, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: